about
GSK-3 as potential target for therapeutic intervention in cancerAdvances in targeting signal transduction pathwaysRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.The MLL partial tandem duplication in acute myeloid leukaemia.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs.The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapyGlycobiology in malignant gliomas: expression and functions of galectins and possible therapeutic options.Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.PKR activity is required for acute leukemic cell maintenance and growth: a role for PKR-mediated phosphatase activity to regulate GSK-3 phosphorylation.GSK-3beta is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity.AML1/ETO promotes the maintenance of early hematopoietic progenitors in NOD/SCID mice but does not abrogate their lineage specific differentiation.Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma.[Occlusion of the femoral arteries in de novo AML].[Polycythemia vera and D-dimer-negative thromboembolism].Primary osteomyelofibrosis and an XX-male genotype.
P50
Q27013811-1587060C-DC1D-474F-979A-8A0C7E905ADDQ27686983-9D7AFD9A-5909-445B-9FCB-60EA8BB2DE26Q34307356-18676CE3-D02F-429E-AC54-A8FD36E71886Q34966603-5F366794-73AC-4D76-9073-44EA1047BFCEQ35679353-E3DC2D32-3245-4786-8F9A-92D93631A19BQ36590734-912208EA-766B-47D8-BA6D-58039755E910Q36862768-48DDCE0D-2AB3-4947-B2C7-54FF408DB04FQ36973814-7F131F6A-7EA7-46F8-83B0-F36B49E54EEDQ37192602-DAA33941-E467-4881-BEFA-95A576214C14Q37192611-A321AF1D-CC66-4150-9C0A-7FF0FEE1C2EBQ37192616-F584ED52-FAF0-433F-8BEC-287DCC0E13ACQ37878532-4B058114-BC1F-4C87-AEF8-8B1CD9C0CCF6Q38156313-3C8528E9-06C3-42A3-AF44-0B98FA4A466FQ39841023-29D1A70F-DEA7-421D-8C2C-E7EFB525B34FQ39951275-95228695-3BC0-4304-AF65-66DF998CF8DAQ45204173-1509CABA-3B85-45F2-8098-AD98205D3115Q46715129-F24BF535-31FC-4F63-BA2F-D5CF8CE6E2BDQ48744339-99024EA5-8119-470D-A688-EF59008CA416Q48744956-3819E397-D653-42F2-8BE1-39BD9231BC73Q51040297-7E860B03-DAB1-4D92-B77F-88A2498F5397
P50
name
Jörg Bäsecke
@ast
Jörg Bäsecke
@en
Jörg Bäsecke
@nl
type
label
Jörg Bäsecke
@ast
Jörg Bäsecke
@en
Jörg Bäsecke
@nl
prefLabel
Jörg Bäsecke
@ast
Jörg Bäsecke
@en
Jörg Bäsecke
@nl